Ira L. Kraft

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Jamshid S. Khorashad, Todd W. Kelley, Philippe Szankasi et al. · Blood · 2012 · 223 citations

Medicine, Molecular Biology, Oncology +14

Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence

Sneha Ramakrishna, Steven L. Highfill, Zachary Walsh et al. · Clinical Cancer Research · 2019 · 175 citations · Full text

Life Sciences, Immunology, Oncology +17

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

Anna M. Eiring, Brent D. G. Page, Ira L. Kraft et al. · Leukemia · 2014 · 133 citations · Full text

Medicine, Oncology, Pharmacology +12

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance

Jamshid S. Khorashad, Anna M. Eiring, Clinton C. Mason et al. · Blood · 2015 · 44 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +12

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

Anna M. Eiring, Jamshid S. Khorashad, David Anderson et al. · Leukemia · 2015 · 43 citations

Medicine, Cancer Biology, Oncology +16